Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
PART1
Specific or universal ncRNAs
Universal ncRNAs
Class
Long noncoding RNA
Biomarker
Yes
Biomarker application
Treatment
Upstream regulatory factors
Not available
Downstream target
miR-129/Bcl-2
Cancer name
Esophageal Squamous Cell Carcinoma
Cancer site
Esophagus
Treatment type
Chemotherapy
Drug
Gefitinib
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
LncRNA PART1 promotes gefitinib resistance by regulating miR-129/Bcl-2 pathway, and may serve as a therapeutic target for ESCC patients.
Tissue resource
serum samples were collected from advanced esophageal squamous cell carcinoma patients who received gefitinib treatment
human esophageal squamous cell carcinoma cell lines TE1
human esophageal squamous cell carcinoma cell lines TE6
human esophageal squamous cell carcinoma cell lines TE8
human esophageal squamous cell carcinoma cell lines TTn
human esophageal squamous cell carcinoma cell lines KYSE-450
Experiment
qRT-PCR,Western blot
Institute
the Affiliated Hospital of Southwest Medical University
the Chinese Type Culture Collection, Chinese Academy of Sciences
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.